Our study found that the serum Wnt5a protein level of newly diagnosed type 2 diabetes patients was significantly increased after the intervention of the GLP-1RA compared with before treatment, and the Sfrp5 was lower than that of the control group. This evidence concerns the gene SFRP5 and type 2 diabetes mellitus.